News articles about Incyte (NASDAQ:INCY) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Incyte earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.9257749403192 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

Shares of Incyte (NASDAQ INCY) traded up $0.33 on Wednesday, reaching $96.62. The company had a trading volume of 1,346,200 shares, compared to its average volume of 1,470,000. The stock has a market cap of $20,390.00, a PE ratio of -120.78 and a beta of 0.74. Incyte has a 1 year low of $92.91 and a 1 year high of $153.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81.

Incyte (NASDAQ:INCY) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.11. The firm had revenue of $381.50 million for the quarter, compared to analysts’ expectations of $360.34 million. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. Incyte’s revenue was up 41.6% on a year-over-year basis. During the same quarter last year, the business posted $0.19 EPS. equities analysts anticipate that Incyte will post -1.32 EPS for the current year.

A number of research analysts have recently commented on INCY shares. Argus reissued a “buy” rating and set a $150.00 price target on shares of Incyte in a report on Wednesday, September 13th. Royal Bank of Canada began coverage on Incyte in a report on Thursday, September 14th. They set a “sector perform” rating and a $136.00 price target on the stock. Jefferies Group reaffirmed a “buy” rating on shares of Incyte in a report on Friday, October 6th. Goldman Sachs Group began coverage on Incyte in a report on Friday, October 6th. They set a “buy” rating and a $160.00 target price on the stock. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Incyte in a report on Wednesday, October 25th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $143.11.

In related news, insider David W. Gryska sold 6,760 shares of Incyte stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $98.87, for a total value of $668,361.20. Following the transaction, the insider now owns 20,752 shares of the company’s stock, valued at approximately $2,051,750.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David W. Gryska sold 3,915 shares of Incyte stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $105.63, for a total value of $413,541.45. The disclosure for this sale can be found here. Insiders sold a total of 44,878 shares of company stock worth $4,636,494 in the last three months. 17.70% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: This news story was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Insider Buying and Selling by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with's FREE daily email newsletter.